256 related articles for article (PubMed ID: 19577712)
1. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy.
Townsend D; Yasuda S; Chamberlain J; Metzger JM
Trends Cardiovasc Med; 2009 Feb; 19(2):50-55. PubMed ID: 19577712
[TBL] [Abstract][Full Text] [Related]
2. Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.
Wasala NB; Bostick B; Yue Y; Duan D
Hum Mol Genet; 2013 Jul; 22(13):2634-41. PubMed ID: 23459935
[TBL] [Abstract][Full Text] [Related]
3. Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.
Fayssoil A; Nardi O; Orlikowski D; Annane D
Heart Fail Rev; 2010 Jan; 15(1):103-7. PubMed ID: 19943106
[TBL] [Abstract][Full Text] [Related]
4. Clinical Manifestations and Overall Management Strategies for Duchenne Muscular Dystrophy.
Tsuda T
Methods Mol Biol; 2018; 1687():19-28. PubMed ID: 29067653
[TBL] [Abstract][Full Text] [Related]
5. Micro-dystrophin gene therapy prevents heart failure in an improved Duchenne muscular dystrophy cardiomyopathy mouse model.
Howard ZM; Dorn LE; Lowe J; Gertzen MD; Ciccone P; Rastogi N; Odom GL; Accornero F; Chamberlain JS; Rafael-Fortney JA
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651713
[TBL] [Abstract][Full Text] [Related]
6. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle.
Townsend D; Yasuda S; Li S; Chamberlain JS; Metzger JM
Mol Ther; 2008 May; 16(5):832-5. PubMed ID: 18414480
[TBL] [Abstract][Full Text] [Related]
7. Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne Muscular Dystrophy.
Meyers TA; Townsend D
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31443395
[TBL] [Abstract][Full Text] [Related]
8. Na
Bkaily G; Jacques D
Can J Physiol Pharmacol; 2017 Oct; 95(10):1213-1223. PubMed ID: 28727929
[TBL] [Abstract][Full Text] [Related]
9. The multifaceted view of heart problem in Duchenne muscular dystrophy.
Florczyk-Soluch U; Polak K; Dulak J
Cell Mol Life Sci; 2021 Jul; 78(14):5447-5468. PubMed ID: 34091693
[TBL] [Abstract][Full Text] [Related]
10. What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?
Wells DJ
J Muscle Res Cell Motil; 2019 Jun; 40(2):141-150. PubMed ID: 31289969
[TBL] [Abstract][Full Text] [Related]
11. A novel mouse model of Duchenne muscular dystrophy carrying a multi-exonic
Wong TWY; Ahmed A; Yang G; Maino E; Steiman S; Hyatt E; Chan P; Lindsay K; Wong N; Golebiowski D; Schneider J; Delgado-Olguín P; Ivakine EA; Cohn RD
Dis Model Mech; 2020 Sep; 13(9):. PubMed ID: 32988972
[TBL] [Abstract][Full Text] [Related]
12. Uniform low-level dystrophin expression in the heart partially preserved cardiac function in an aged mouse model of Duchenne cardiomyopathy.
Wasala NB; Yue Y; Vance J; Duan D
J Mol Cell Cardiol; 2017 Jan; 102():45-52. PubMed ID: 27908661
[TBL] [Abstract][Full Text] [Related]
13. Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
Parvatiyar MS; Marshall JL; Nguyen RT; Jordan MC; Richardson VA; Roos KP; Crosbie-Watson RH
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26702077
[TBL] [Abstract][Full Text] [Related]
14. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
[TBL] [Abstract][Full Text] [Related]
15. Dystrophin analysis in carriers of Duchenne and Becker muscular dystrophy.
Hoogerwaard EM; Ginjaar IB; Bakker E; de Visser M
Neurology; 2005 Dec; 65(12):1984-6. PubMed ID: 16380627
[TBL] [Abstract][Full Text] [Related]
16. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
Duan D
Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
[TBL] [Abstract][Full Text] [Related]
17. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure.
Townsend D; Blankinship MJ; Allen JM; Gregorevic P; Chamberlain JS; Metzger JM
Mol Ther; 2007 Jun; 15(6):1086-92. PubMed ID: 17440445
[TBL] [Abstract][Full Text] [Related]
19. DMD carrier model with mosaic dystrophin expression in the heart reveals complex vulnerability to myocardial injury.
Meyers TA; Heitzman JA; Townsend D
Hum Mol Genet; 2020 Apr; 29(6):944-954. PubMed ID: 31976522
[TBL] [Abstract][Full Text] [Related]
20. Duchenne muscular dystrophy: pathogenesis and promising therapies.
Chang M; Cai Y; Gao Z; Chen X; Liu B; Zhang C; Yu W; Cao Q; Shen Y; Yao X; Chen X; Sun H
J Neurol; 2023 Aug; 270(8):3733-3749. PubMed ID: 37258941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
